Advertisement

Surgery pp 1317-1336 | Cite as

Pathobiology of Vascular Disease

  • Bryan W. Tillman
  • Randolph L. Geary

Abstract

Knowledge of the structure and function of the circulatory system and the consequences of temporary or permanent disruption of regional blood flow is imperative in surgery because operative procedures by their very nature disrupt tissues and their blood supply. Moreover, reconstruction of blood vessels is often necessary as they fail from disease or trauma. Repair or replacement requires an understanding of vascular anatomy, vessel wall structure, hemodynamics, and the healing properties of vessels and grafts. This chapter focuses on the arterial system, providing an overview of its origin, structure, and function. The pathobiology of common artery wall diseases is then considered. Subsequent chapters focus on contemporary evidence-based management of regional artery wall pathology.

Keywords

Smooth Muscle Cell Abdominal Aortic Aneurysm Vein Graft Intimal Hyperplasia Artery Wall 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685–693.PubMedGoogle Scholar
  2. 2.
    Baldwin HS. Early embryonic vascular development. Cardiovasc Res 1996;31(suppl S):E34–E45.PubMedGoogle Scholar
  3. 3.
    Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Biol 1995;11:73–91.Google Scholar
  4. 4.
    Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3(7):643–651.PubMedGoogle Scholar
  5. 5.
    Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004;95:449–458.PubMedGoogle Scholar
  6. 6.
    Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500–1502.PubMedGoogle Scholar
  7. 7.
    Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995;75:487–517.PubMedGoogle Scholar
  8. 8.
    Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997;99:373–376.PubMedGoogle Scholar
  9. 9.
    Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990;70:1177–1210.PubMedGoogle Scholar
  10. 10.
    Schwartz SM, Benditt EP. Clustering of replicating cells in aortic endothelium. Proc Natl Acad Sci USA 1976;73:651–653.PubMedGoogle Scholar
  11. 11.
    Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327–333.PubMedGoogle Scholar
  12. 12.
    Raines EW, Ross R. Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? BioEssays 1996;18:271–282.PubMedGoogle Scholar
  13. 13.
    Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106–113.PubMedGoogle Scholar
  14. 14.
    Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:919–925.PubMedGoogle Scholar
  15. 14A.
    Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005;438:937–945.PubMedGoogle Scholar
  16. 14B.
    Wigle JT, Harvey N, Detmar M, et al. An essential role for Proxl in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002;21:1505–1513.PubMedGoogle Scholar
  17. 15.
    Vernon RB, Sage EH. Between molecules and morphology—extracellular matrix and creation of vascular form. Am J Pathol 1995;147:873–883.PubMedGoogle Scholar
  18. 16.
    Ruoslahti E, Engvall E. Integrins and vascular extracellular matrix assembly. J Clin Invest 1997;99:1149–1152.PubMedGoogle Scholar
  19. 17.
    Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 1994;77:477–478.PubMedGoogle Scholar
  20. 18.
    Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAFl/CIPl expression by vascular cell integrin alphavbeta3 during angiogenesis. J Clin Invest 1996;98:426–433.PubMedGoogle Scholar
  21. 19.
    Schwartz SM, DeBlois D, O’Brien ERM. The intima—soil for atherosclerosis and restenosis. Circ Res 1995;77:445–465.PubMedGoogle Scholar
  22. 20.
    Friedman MH, Hutchins GM, Bargeron CB, Deters OJ, Mark FF. Correlation between intimal thickness and fluid shear in human arteries. Atherosclerosis 1981;39:425–436.PubMedGoogle Scholar
  23. 21.
    Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996;47:315–331.PubMedGoogle Scholar
  24. 22.
    Zimmerman GA, Mclntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1996;98:1699–1702.PubMedGoogle Scholar
  25. 23.
    Gimbrone MA, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997;99:1809–1813.PubMedGoogle Scholar
  26. 24.
    Resnick N, Gimbrone MA Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J 1995;9:874–882.PubMedGoogle Scholar
  27. 25.
    Wolinsky H, Glagov S. A lamellar unit of aortic medial structure and function in mammals. Circ Res 1967;20:99–111.PubMedGoogle Scholar
  28. 26.
    Fung YC, Liu SQ. Determination of the mechanical properties of the different layers of blood vessels in vivo. Proc Natl Acad Sci USA 1995;92:2169–2173.PubMedGoogle Scholar
  29. 27.
    Clarke JA. An x-ray microscopic study of the postnatal development of the vasa vasorum in the human aorta. J Anat 1965;99:877–889.PubMedGoogle Scholar
  30. 28.
    Williams JK, Heistad DD. Structure and function of vasa vasorum. Trends Cardiovasc Med 1996;6:53–57.Google Scholar
  31. 29.
    Bo WJ, McKinney WM, Bowden RL. The origin and distribution of vasa vasorum at the bifurcation of the common carotid artery with atherosclerosis. Stroke 1989;20:1484–1487.PubMedGoogle Scholar
  32. 30.
    Langille BL, O’Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405–407.PubMedGoogle Scholar
  33. 31.
    Langille BL. Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix. J Cardiovasc Pharmacol 1993;21(suppl 1):S11–S17.PubMedGoogle Scholar
  34. 32.
    Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995;75:519–560.PubMedGoogle Scholar
  35. 33.
    Traub O, Berk BC. Laminar shear stress. Mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998;18:677–685.PubMedGoogle Scholar
  36. 34.
    Mulvany MJ. Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. J Hum Hypertens 1995;9:479–485.PubMedGoogle Scholar
  37. 35.
    Mondy JS, Lindner V, Miyashiro J, Berk BC, Dean RH, Geary RL. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997;81:320–327.PubMedGoogle Scholar
  38. 36.
    Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115–125.PubMedGoogle Scholar
  39. 37.
    Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kollettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371–1375.PubMedGoogle Scholar
  40. 38.
    Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994;271:289–294.PubMedGoogle Scholar
  41. 38A.
    http://www.who.int/mediacentre/news/releases/pr83/en/ 17 October 2002.Google Scholar
  42. 39.
    American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas: American Heart Association, 2005.Google Scholar
  43. 40.
    Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004;110(3):265–270.PubMedGoogle Scholar
  44. 41.
    Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369–377, 420–425.PubMedGoogle Scholar
  45. 42.
    Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993–1007.PubMedGoogle Scholar
  46. 43.
    Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004;110:1868–1873.PubMedGoogle Scholar
  47. 44.
    Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13:125–138.PubMedGoogle Scholar
  48. 44A.
    Pitman WA, Osgood DP, Smith D, et al. The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in FIB hamsters. Atherosclerosis 1998;138(1):43–52.PubMedGoogle Scholar
  49. 44B.
    Stein Y, Stein O. Does therapeutic intervention achieve slowing of progression or bona fide regression of atherosclerotic lesions? Arterioscler Thromb Vasc Biol 2001;21:183–188.PubMedGoogle Scholar
  50. 45.
    McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991;84:1273–1278.PubMedGoogle Scholar
  51. 46.
    Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986;232:87–90.PubMedGoogle Scholar
  52. 47.
    Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426–2431.PubMedGoogle Scholar
  53. 48.
    Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388–391.PubMedGoogle Scholar
  54. 49.
    Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis. Basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995;91:2488–2496.PubMedGoogle Scholar
  55. 50.
    Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63(4):582–592.PubMedGoogle Scholar
  56. 51.
    Gotto AM. Antioxidants, statins, and atherosclerosis. J Am Coll Cardiol 2003;41:1205–1210.PubMedGoogle Scholar
  57. 51A.
    Napoli C, Lerman LO, de Nigris F, et al. Rethinking primary prevention of atherosclerosis-related diseases. Circulation 2006;114(23):2517–2527.PubMedGoogle Scholar
  58. 51B.
    Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16–22.PubMedGoogle Scholar
  59. 51C.
    Willigendael EM, Teijink JAW, Bartelink MEL, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004;40:1158–1165.PubMedGoogle Scholar
  60. 51D.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.Google Scholar
  61. 51E.
    Adler Al, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894–899.PubMedGoogle Scholar
  62. 51F.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatine in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.Google Scholar
  63. 51G.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.PubMedGoogle Scholar
  64. 51H.
    S. Yusuf P, Sleight J, Pogue O, et al. Heart Outcomes Prevention Evaluation Study Investigators, effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes. N Engl J Med 2000;342:145–153.PubMedGoogle Scholar
  65. 51I.
    Roberts DH, Tsao Y, McLoughlin GA, et al. Placebo-controlled comparison of captopril, atenolol, labetolol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2(8560):650–653.PubMedGoogle Scholar
  66. 51J.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA 2000;284:1263–1270.PubMedGoogle Scholar
  67. 51K.
    Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113(19):2363–2372.PubMedGoogle Scholar
  68. 52.
    Pearson TA. New tools for coronary risk assessment: what are their advantages and limitations? Circulation 2002;105:886–892.PubMedGoogle Scholar
  69. 53.
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.PubMedGoogle Scholar
  70. 54.
    Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236.PubMedGoogle Scholar
  71. 55.
    Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. The Homocyseine and Progression of Atherosclerosis Study Investigators. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8–21.PubMedGoogle Scholar
  72. 56.
    Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009–1015.PubMedGoogle Scholar
  73. 57.
    Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178–182.PubMedGoogle Scholar
  74. 57A.
    Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006;48(5):914–923.PubMedGoogle Scholar
  75. 58.
    Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 2004;24:338–343.PubMedGoogle Scholar
  76. 59.
    Campbell LA, O’Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585–588.PubMedGoogle Scholar
  77. 60.
    Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation 2004;109:1010–1015.PubMedGoogle Scholar
  78. 60A.
    Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A Metaanalysis of randomized controlled trials. JAMA 2005;293:2641–2647.PubMedGoogle Scholar
  79. 61.
    McMillan DE. Blood flow and the localization of atherosclerotic plaques. Stroke 1985;16:582–587.PubMedGoogle Scholar
  80. 62.
    Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb 1992;12:120–134.PubMedGoogle Scholar
  81. 63.
    Truskey GA, Herrmann RA, Kait J, Barber KM. Focal increases in vascular cell adhesion molecule-1 and intimal macrophages at atherosclerosis-susceptible sites in rabbit aorta after short-term cholesterol feeding. Arterioscler Thromb Vasc Biol 1999;19:393–401.PubMedGoogle Scholar
  82. 64.
    Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Atherosclerosis 1989;9(1 suppl):119–132.Google Scholar
  83. 65.
    Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996;16:4–11.PubMedGoogle Scholar
  84. 66.
    O’Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996;93:672–682.PubMedGoogle Scholar
  85. 67.
    Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003;100:4736–4741.PubMedGoogle Scholar
  86. 68.
    Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161–1170.PubMedGoogle Scholar
  87. 69.
    Luo G, Ducy P, McKee M, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature (Lond) 1997;385:78–81.Google Scholar
  88. 70.
    Losordo DW, Rosenfield K, Kaufman J, Pieczek A, Isner JM. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis: in vivo documentation using intravascular ultrasound. Circulation 1994;89:2570–2577.PubMedGoogle Scholar
  89. 71.
    Pasterkamp G, Borst C, Post Mf, et al. Atherosclerotic arterial remodeling in the superficial femoral artery—individual variation in local compensatory enlargement response. Circulation 1996;93:1818–1825.PubMedGoogle Scholar
  90. 72.
    Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–671.PubMedGoogle Scholar
  91. 73.
    Davies MJ, Thomas AC. Plaque Assuring: the cause of acute myocardial infarction, sudden death, and crescendo angina. Br Heart J 1985;53:363–373.PubMedGoogle Scholar
  92. 74.
    Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354–1363.PubMedGoogle Scholar
  93. 75.
    Mann JM, Davies MJ. Vulnerable plaque—relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996;94:928–931.PubMedGoogle Scholar
  94. 76.
    Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276–1282.PubMedGoogle Scholar
  95. 77.
    Nicholls SC, Kohler TR, Bergelin RO, Primozich JF, Lawrence RL, Strandness DE Jr. Carotid artery occlusion: natural history. J Vasc Surg 1986,4:479–485.Google Scholar
  96. 78.
    Pai RG, Heywood JT. Atheroembolism. N Engl M Med 1995;333:852.Google Scholar
  97. 79.
    Moliterno DJ, Topol EJ. Restenosis: epidemiology and treatment. In: Topol EJ, ed. Textbook of Cardiovascular Medicine, 2nd ed. Philadelphia: Lippincott-Raven, 2002.Google Scholar
  98. 80.
    Weintraub WS, Ghazzal ZMB, Douglas JS, et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation 1993;87:831–840.PubMedGoogle Scholar
  99. 81.
    Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616–623.PubMedGoogle Scholar
  100. 82.
    Carballo RE, Towne JB, Seabrook GR, Freischlag JA, Cambria RA. An outcome analysis of carotid endarterectomy: the incidence and natural history of recurrent stenosis. J Vasc Surg 1996;23:749–753.PubMedGoogle Scholar
  101. 83.
    Healy DA, Zierler RE, Nicholls SC, et al. Long-term follow-up and clinical outcome of carotid restenosis. J Vasc Surg 1989;10:662–669.PubMedGoogle Scholar
  102. 84.
    Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561–566.PubMedGoogle Scholar
  103. 85.
    Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–495.PubMedGoogle Scholar
  104. 86.
    Sheppard R, Eisenberg MJ, Donath D, Meerkin D. Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization. Am Heart J 2003;146:775–786.PubMedGoogle Scholar
  105. 87.
    Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–1323.PubMedGoogle Scholar
  106. 88.
    Colombo A, Drzewiecki J, Banning A, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788–794.PubMedGoogle Scholar
  107. 88A.
    Slavin L, Chhabra A, Tobis J. Drug-eluting stents: Preventing restenosis. Cardiol Rev 2007;25(1):1–12Google Scholar
  108. 88B.
    Duda, SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versu bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16(3):331–338.PubMedGoogle Scholar
  109. 89.
    Geary RL, Nikkari ST, Wagner WD, Williams JK, Adams MR, Dean RH. Wound healing: a paradigm for lumen narrowing following arterial reconstruction. J Vasc Surg 1997;27:96–108.Google Scholar
  110. 90.
    Clowes AW, Kamovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature (Lond) 1977;265:625–626.PubMedGoogle Scholar
  111. 91.
    Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507–511.PubMedGoogle Scholar
  112. 92.
    Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129–1132.PubMedGoogle Scholar
  113. 93.
    Powell JS, Clozel JP, Muller RKM, et al. inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186–188.PubMedGoogle Scholar
  114. 94.
    Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial. Circulation 1994;90:908–914.PubMedGoogle Scholar
  115. 95.
    Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;25:362–369.PubMedGoogle Scholar
  116. 96.
    Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809–2815.PubMedGoogle Scholar
  117. 97.
    Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816–2821.PubMedGoogle Scholar
  118. 98.
    Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995;76:996–1002.PubMedGoogle Scholar
  119. 99.
    Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty. A serial intravascular ultrasound study. Circulation 1996;94:35–43.PubMedGoogle Scholar
  120. 100.
    Geary RL, Williams JK, Golden D, Brown DG, Benjamin ME, Adams MR. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis: a nonhuman primate model of restenosis. Arterioscler Thromb Vasc Biol 1996;16:34–43.PubMedGoogle Scholar
  121. 101.
    Mondy JS, Williams JK, Adams MR, Dean RH, Geary RL. Structural determinants of lumen narrowing following angioplasty in atherosclerotic nonhuman primates. J Vasc Surg 1997;26:875–883.PubMedGoogle Scholar
  122. 102.
    Post MJ, Borst C, Pasterkamp G, Haudenschild CC. Arterial remodeling in atherosclerosis and restenosis: a vague concept of a distinct phenomenon. Atherosclerosis 1995;118(suppl):S115–S123.PubMedGoogle Scholar
  123. 103.
    Carrel A, Guthrie CC. Uniterminal and biterminal venous transplantations. Surg Gynecol Obstet 1906;2:266–286.Google Scholar
  124. 104.
    Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lesperance J. Long-term fate of bypass grafts: the coronary artery surgery study (CASS) and Montreal Heart Institute experiences. Circulation 1985;72:V-71–V-78.Google Scholar
  125. 105.
    Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987;5:126–136.PubMedGoogle Scholar
  126. 106.
    Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit vein grafts. Arteriosclerosis 1989;9:374–379.PubMedGoogle Scholar
  127. 107.
    Dobrin PB, Littooy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery (St. Louis) 1989;105:393–400.PubMedGoogle Scholar
  128. 108.
    Gait SW, Zwolak RM, Wagner RJ, Gilbertson JJ. Differential response of arteries and vein grafts to blood flow reduction. J Vasc Surg 1993;17:563–570.Google Scholar
  129. 109.
    Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen PO. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 1995;59:35–42.PubMedGoogle Scholar
  130. 110.
    Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995;92:4502–4506.PubMedGoogle Scholar
  131. 111.
    O’Donohoe MK, Schwartz LB, Radic ZS, Mikat EM, McCann RL, Hagen P-O. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann Surg 1991;214:727–732.Google Scholar
  132. 112.
    Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324–1332.PubMedGoogle Scholar
  133. 113.
    McCollum C, Alexander C, Dip N, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 1991;13:150–162.PubMedGoogle Scholar
  134. 114.
    Muluk SC, Vorp DA, Severyn DA, Gleixner S, Johnson PC, Webster MW. Enchancement of tissue factor expression by vein segments exposed to coronary arterial hemodynamics. J Vasc Surg 1998;27:521–527.PubMedGoogle Scholar
  135. 115.
    DeWeese JA, Leather R, Porter J. Practice guidelines: lower extremity revascularization. J Vasc Surg 1993;18:280–294.PubMedGoogle Scholar
  136. 116.
    Clowes AW, Gown AM, Hanson SR, Reidy MA. Mechanisms of arterial graft failure. I. Role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol 1985;118:43–54.PubMedGoogle Scholar
  137. 117.
    Herring M, Smith J, Dalsing M, et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J Vasc Surg 1994;20:650–655.PubMedGoogle Scholar
  138. 118.
    Kohler TR, Kirkman TR, Kraiss LW, Zierler BK, Clowes AW. Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. Circ Res 1991;69:1557–1565.PubMedGoogle Scholar
  139. 119.
    Geary RL, Kohler TR, Vergel S, Kirkman TR, Clowes AW. Time course of flow-induced smooth muscle cell proliferation and intimal thickening in endothelialized baboon vascular grafts. Circ Res 1994;74:14–23.PubMedGoogle Scholar
  140. 120.
    Mattson EJR, Geary RL, Kraiss LW, et al. Is smooth muscle growth in primate arteries regulated by endothelial nitric oxide synthase? J Vasc Surg 1998;28:514–521.Google Scholar
  141. 121.
    Kraiss LW, Geary RL, Mattsson EJR, Vergel S, Au YPT, Clowes AW. Acute reduction in blood flow and shear stress induce PDGF-A expression in baboon prosthetic grafts. Circ Res 1996;79:45–53.PubMedGoogle Scholar
  142. 122.
    Hart CE, Kraiss LW, Vergel S, et al. PDGFb receptor blockade inhibits intimal hyperplasia in the baboon. Circ Res 1999;99:564–569.Google Scholar
  143. 123.
    Rasmussen TE, Hallett JW. Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997;225:155–164.PubMedGoogle Scholar
  144. 124.
    Scott RAP, Tisi PV, Ashton HA, Allen DR. Abdominal aortic aneurysm rupture rates: a 7-year follow-up of the entire abdominal aortic aneurysm population detected by screening. J Vasc Surg 1998;28:124–128.PubMedGoogle Scholar
  145. 125.
    Alcorn HG, Wolfson SW, Sutton-Tyrell K, Kuller LH, O’Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996;16:963–970.PubMedGoogle Scholar
  146. 126.
    Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997;150:993–1007.PubMedGoogle Scholar
  147. 127.
    Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg 2002;39:110–230.PubMedGoogle Scholar
  148. 128.
    Newman KM, Malon AM, Shin RD, Scholes JV, Ramey WG, Tilson MD. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 1994;30:265–276.PubMedGoogle Scholar
  149. 129.
    Irizarry E, Newman KM, Gandhi RH, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993;54:571–574.PubMedGoogle Scholar
  150. 130.
    Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403–434.PubMedGoogle Scholar
  151. 131.
    Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J 1993;7:1208–1218.PubMedGoogle Scholar
  152. 131A.
    Kelly BA, Bond BC, Poston L. Aortic adaptation to pregnancy: elevated expression of matrix metalloproteinases-2 and-3 in rat gestation. Molecular Human Reproduction 2004;10(5):331–337.PubMedGoogle Scholar
  153. 131B.
    Manallo-Estrella P and Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol 1967;83:336–341.Google Scholar
  154. 131C.
    Hunsaker DM, Turner S, Hunsaker JC. Sudden and unexpected death resulting from splenic artery aneurysm rupture: two case reports of pregnancy-related fatal rupture of splenic artery aneurysm. Am J Forensic Med Pathol 2002;23(4):338–341.PubMedGoogle Scholar
  155. 132.
    Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997;95:205–212.PubMedGoogle Scholar
  156. 133.
    Curci JA, Thompson RW. Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context? J Clin Invest 2004;114:168–171.PubMedGoogle Scholar
  157. 134.
    Hirose H, Ozsvath KJ, Xia S, Gaetz HP, Tilson MD. Immunoreactivity of adventitial matrix fibrils of normal and aneurysmal abdominal aorta with antibodies against vitronectin and fibrinogen. Pathobiology 1998;66:1–4.PubMedGoogle Scholar
  158. 135.
    Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamidia pneumoniae in aortic lesions of atherosclerosis by immunohistochemical stain. Arterioscler Thromb 1993;13:1501–1504.PubMedGoogle Scholar
  159. 136.
    Gomes MN, Choyke PL, Wallace RB. Infected aortic aneurysms. A changing entity. Ann Surg 1992;215:435–442.PubMedGoogle Scholar
  160. 137.
    Valentine RJ, Clagett GP. Aortic graft infections: replacement with autogenous vein. Cardiovasc Surg 2001;9:419–425.PubMedGoogle Scholar
  161. 137A.
    Marques da Silva R, Caugant DA, Eribe ER, et al. Bacterial diversity in aortic aneurysms determined by 16S ribosomal RNA gene analysis. J Vasc Surg 2006;44(5):1055–1060.PubMedGoogle Scholar
  162. 138.
    Farkas J, Fichelle J, Laurian C, et al. Long-term follow-up of positive cultures in 500 abdominal aortic aneurysms. Arch Surg 1993;128:284–288.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Bryan W. Tillman
    • 1
  • Randolph L. Geary
    • 2
  1. 1.Department of SurgeryWake Forest University Medical CenterWinston-SalemUSA
  2. 2.Department of General SurgeryWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations